Ventrus Biosciences Inc.
This article was originally published in Start Up
Executive Summary
Like other start-up companies working to develop drugs for GI disorders, Ventrus Biosciences was attracted to the sector not only by unmet clinical needs and the focused sales opportunities, but also by the potential for creating a cross-over success: a drug that launches as a prescription product but eventually leaps over the counter to become a blockbuster, á la Claritin. Ventrus has two drug candidates ready for Phase III testing: a topical gel formulation of diltiazem, a generic vasodilator, as a treatment for anal fissures, and a novel compound it hopes will become the first new product approved for hemorrhoids in 30 years.
You may also be interested in...
Ventrus Could Start Pivotal Trial For Rx Hemorrhoid Therapy Mid-Year
The novel 5HT2a receptor antagonist would be the first FDA approved therapy for acute, non-surgical hemorrhoids, though intra-anal steroids are prescribed off-label for symptomatic relief.
Ventrus Could Start Pivotal Trial For Rx Hemorrhoid Therapy Mid-Year
The novel 5HT2a receptor antagonist would be the first FDA approved therapy for acute, non-surgical hemorrhoids, though intra-anal steroids are prescribed off-label for symptomatic relief.
Ventrus Could Start Pivotal Trial For Rx Hemorrhoid Therapy Mid-Year
Ventrus Biosciences Inc. is ready to take its lead candidate iferanserin, a novel compound aimed at arresting hemorrhoid symptoms rather than soothing them, into Phase III studies after the micro-cap biotech's late-December initial public offering brought in $20 million to support the program.